ATE234632T1 - Regulierung der immunoglobulinproduktion durch interleukin-9 - Google Patents

Regulierung der immunoglobulinproduktion durch interleukin-9

Info

Publication number
ATE234632T1
ATE234632T1 AT98200841T AT98200841T ATE234632T1 AT E234632 T1 ATE234632 T1 AT E234632T1 AT 98200841 T AT98200841 T AT 98200841T AT 98200841 T AT98200841 T AT 98200841T AT E234632 T1 ATE234632 T1 AT E234632T1
Authority
AT
Austria
Prior art keywords
interleukin
production
regulation
immunoglobulin production
ige
Prior art date
Application number
AT98200841T
Other languages
English (en)
Inventor
Bernard Dugas
Catherine Druez
Pierre Braquet
Catherine Uyttenhove
Snick Charles Van
Jean-Michel Mencia-Huerta
Jean-Christophe Renauld
Original Assignee
Ludwig Inst Cancer Res
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Sod Conseils Rech Applic filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE234632T1 publication Critical patent/ATE234632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98200841T 1990-10-05 1991-10-01 Regulierung der immunoglobulinproduktion durch interleukin-9 ATE234632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/593,238 US5132109A (en) 1990-10-05 1990-10-05 Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof

Publications (1)

Publication Number Publication Date
ATE234632T1 true ATE234632T1 (de) 2003-04-15

Family

ID=24373963

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91918691T ATE182079T1 (de) 1990-10-05 1991-10-01 Regulierung der immunoglobulinproduktion durch interleukin-9
AT98200841T ATE234632T1 (de) 1990-10-05 1991-10-01 Regulierung der immunoglobulinproduktion durch interleukin-9

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT91918691T ATE182079T1 (de) 1990-10-05 1991-10-01 Regulierung der immunoglobulinproduktion durch interleukin-9

Country Status (11)

Country Link
US (1) US5132109A (de)
EP (2) EP0553198B1 (de)
JP (2) JP3205754B2 (de)
AT (2) ATE182079T1 (de)
AU (2) AU646509B2 (de)
CA (1) CA2093434C (de)
DE (2) DE69133225T2 (de)
DK (2) DK0553198T3 (de)
ES (2) ES2136065T3 (de)
GR (1) GR3031518T3 (de)
WO (1) WO1992005698A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131719C (en) * 1992-03-09 2003-09-16 Jean-Christophe Renauld Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
US6911887B1 (en) 1994-09-12 2005-06-28 Matsushita Electric Industrial Co., Ltd. Inductor and method for producing the same
AU2007202406B2 (en) * 1995-08-24 2010-08-12 Ligand Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US6037149A (en) 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
ATE307203T1 (de) * 1995-08-24 2005-11-15 Genaera Corp Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
WO1998024904A2 (en) 1996-12-02 1998-06-11 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
EP1401497B1 (de) 2001-06-08 2012-01-11 Genaera Corporation Verfahren zur modulation von il-13
JP4270974B2 (ja) 2003-08-04 2009-06-03 本田技研工業株式会社 車両における燃料タンクの配置構造
US20100219541A1 (en) 2007-09-28 2010-09-02 Konica Minolta Opto, Inc. Method for manufacturing optical device
EP2255941A4 (de) 2008-03-19 2014-05-28 Konica Minolta Opto Inc Verfahren zur herstellung einer wafer-linse
WO2009116448A1 (ja) 2008-03-19 2009-09-24 コニカミノルタオプト株式会社 成形体及びウエハレンズの製造方法
WO2011136138A1 (ja) 2010-04-27 2011-11-03 コニカミノルタオプト株式会社 撮像用レンズ、ウエハレンズ、ウエハレンズ積層体、撮像用レンズの製造方法、撮像用レンズの中間物、撮像用レンズの中間物の製造方法
US9828087B2 (en) * 2016-01-27 2017-11-28 Honeywell International Inc. Systems and methods for ground effect ceiling limit display

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511951A (en) * 1894-01-02 Chusetts
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
WO1991014767A1 (en) * 1990-03-23 1991-10-03 Ludwig Institute For Cancer Research Method for enhanced growth and proliferation of mast cells

Also Published As

Publication number Publication date
DE69131450D1 (de) 1999-08-19
EP0903150B1 (de) 2003-03-19
DE69133225T2 (de) 2004-02-19
AU646509B2 (en) 1994-02-24
ES2136065T3 (es) 1999-11-16
GR3031518T3 (en) 2000-01-31
EP0903150A1 (de) 1999-03-24
US5132109A (en) 1992-07-21
CA2093434A1 (en) 1992-04-06
EP0553198A1 (de) 1993-08-04
CA2093434C (en) 1999-08-10
AU8760791A (en) 1992-04-28
DK0903150T3 (da) 2003-07-21
DE69133225D1 (de) 2003-04-24
DE69131450T2 (de) 2000-03-30
EP0553198B1 (de) 1999-07-14
ES2194273T3 (es) 2003-11-16
JP3205754B2 (ja) 2001-09-04
ATE182079T1 (de) 1999-07-15
JP2001253835A (ja) 2001-09-18
AU656493B2 (en) 1995-02-02
AU5243493A (en) 1994-02-17
EP0553198A4 (en) 1994-08-17
DK0553198T3 (da) 1999-12-27
WO1992005698A1 (en) 1992-04-16
JPH06502404A (ja) 1994-03-17

Similar Documents

Publication Publication Date Title
ATE182079T1 (de) Regulierung der immunoglobulinproduktion durch interleukin-9
AU3674684A (en) Non-catalytic method for reducing the concentration of no in combustion effluents by injecting ammonia at temperatures greater than about 1300 degree k.
ES8206856A1 (es) Mejoras en un metodo y su correspondiente equipo de ensayo para determinar antigenos por medio de una reaccion inmuno- quimica
DE69528888T2 (de) Regulierung von nf-kappa-b aktivität durch proteasome
DE3684211D1 (de)
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
DE69132262D1 (de) Verfahren zur Herstellung eines Halbleiterbauelementes mit zu Source- und Drainelektrode selbstjustiertem Gate
DE69109166T2 (de) Cyanobutylation von Aminen mit 2-Pentennitril.
ES2164211T3 (es) Procedimiento mejorado para la fabricacion de sal de 5-(alcoximetil)piridin-2,3-dicarboxilato.
DE3862547D1 (de) Vorrichtung zur anaeroben behandlung von biomasse.
DK447784A (da) Immuninterferon
DK157276C (da) Fremgangsmaade og anlaeg til stroemforsyning af vekselstroemsnet med en dieselmotor
IT1229123B (it) Tracciante per prodotti petroliferi
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
ATE26411T1 (de) Verfahren fuer die reduzierung des so2- und/oder nox-gehaltes in rauchgas.
IT1143000B (it) Metodo per ottimizzare la combustione di combustibili granulari o in piccolissimi pezzi e impianto per la sua realizzazione
DK511479A (da) Regulering for koeremotor foedet af stroemretter i det svage feltomraade
GB8811342D0 (en) Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
IT7919615V0 (it) Giunto di collegamento e fissaggio ai piantoni dei moduli di cancellate specialmente in acciaio zincato.
ATE31623T1 (de) Injizierbare zusammensetzungen von bbm-928a.
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0903150

Country of ref document: EP

EELA Cancelled due to lapse of time